Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tilray medicinal cannabis refers to GMP-certified botanical cannabis products developed by Tilray Brands (formerly Tilray Canada). In the context of a specific safety assessment study conducted in partnership with the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, these products were evaluated for their impact on driving performance. The study utilized two specific formulations: a high-THC variety and a balanced 1:1 THC:CBD variety, both administered via vaporization. The active components, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), interact with the endocannabinoid system, specifically targeting CB1 and CB2 receptors in the central nervous system. While THC is known for its psychoactive effects and potential for impairment, CBD is non-intoxicating. The driving study concluded that THC-dominant cannabis caused temporary impairment, whereas CBD-dominant cannabis did not significantly affect driving ability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tilray medicinal cannabis.